• Spiroplasma eriocheiris Entry: Clathrin-Dependent and Macrop

  2026-05-06

  Wei et al. (2019) elucidate the cellular entry mechanism of Spiroplasma eriocheiris in Drosophila S2 cells, demonstrating reliance on clathrin-mediated endocytosis and macropinocytosis. Their inhibitor-based approach provides a robust framework for dissecting host-pathogen interactions in invertebrate models, with practical implications for endocytosis research and infectious disease studies.

• Ziprasidone Hydrochloride (A5350): Reliable Assays for Cance

  2026-05-05

  This article delivers scenario-driven guidance for researchers and technicians integrating Ziprasidone Hydrochloride (SKU A5350) into cell viability, proliferation, and cytotoxicity assays. Drawing on quantitative evidence and workflow best practices, it addresses reproducibility, assay optimization, and vendor reliability—demonstrating how this reagent supports sensitive and interpretable data in cancer and neuroscience research.

• Cediranib (AZD2171): Advanced Strategies for VEGFR Pathway R

  2026-05-05

  Cediranib (AZD2171) empowers cancer researchers to dissect VEGFR signaling with unmatched potency and selectivity. This guide delivers actionable protocols, troubleshooting insights, and comparative advantages rooted in recent in vitro evaluation breakthroughs.

• FXR-KLF11 Axis: CDCA’s Mechanistic Role in CI-AKI Protection

  2026-05-04

  This study identifies the FXR-KLF11 axis as central to the protective effects of Chenodeoxycholic Acid (CDCA) against contrast-induced acute kidney injury (CI-AKI). By demonstrating that CDCA-driven FXR activation transcriptionally upregulates KLF11, which in turn suppresses the JAK2/STAT3 pathway, the research advances mechanistic understanding and informs future prophylactic strategies for kidney injury.

• Toremifene vs Tamoxifen: Evidence for Advanced Breast Cancer

  2026-05-04

  The Cochrane review by Mao et al. provides a rigorous comparative analysis of toremifene and tamoxifen for advanced breast cancer, synthesizing randomized controlled trials to evaluate efficacy and safety. This evidence-driven synthesis informs treatment selection and highlights the need for nuanced protocol design in translational oncology.

• Lamotrigine in Mechanistic Neurocardiac Research: Beyond Epi

  2026-05-03

  Explore the advanced applications of Lamotrigine as a sodium channel blocker and 5-HT inhibitor in neurocardiac research. This article uniquely analyzes mechanistic insights and translational considerations for Lamotrigine, providing deeper scientific context than standard epilepsy-focused guides.

• LY2603618: Chk1 Inhibitor Workflows for Enhanced DNA Damage

  2026-05-02

  LY2603618 from APExBIO stands out as a highly selective Chk1 inhibitor, empowering researchers to dissect DNA damage response mechanisms and synergize chemotherapy regimens, especially in non-small cell lung cancer models. Discover stepwise protocols, troubleshooting insights, and real-world applications that maximize reproducibility and performance in advanced oncology workflows.

• Trelagliptin Enhances Osteoblastic Differentiation via RUNX2

  2026-05-01

  The referenced study establishes that Trelagliptin, a DPP-4 inhibitor typically used in diabetes, directly enhances osteoblastic differentiation through RUNX2 upregulation and AMPK signaling in MC3T3-E1 cells. These findings suggest a novel therapeutic avenue for osteoporosis and inform translational workflows requiring precise cell-type isolation.

• ER-Fusogenic Immunogenic Liposomes Enhance Anti-Tumor Immuni

  2026-05-01

  This study introduces phosphatidylinositol-based immunogenic nanoliposomes (PI-INLs) that activate dendritic cells and directly deliver antigens to the endoplasmic reticulum, dramatically boosting CD8 T cell responses in anti-tumor vaccination. The dual-action design addresses the limitations of conventional adjuvants and points to a promising platform for self-adjuvanting nanovaccines.

• D-Luciferin Potassium Salt: Optimizing In Vivo Bioluminescen

  2026-04-30

  D-Luciferin (potassium salt) enables real-time, noninvasive bioluminescence imaging for precise tumor cell tracking and mechanistic cancer studies. Its superior water solubility and high purity make it ideal for both in vivo and in vitro luciferase assays, streamlining workflows across oncology and translational research.

• WY-14643 (Pirinixic Acid) in Metabolic and Inflammation Rese

  2026-04-30

  WY-14643 (Pirinixic Acid) is a benchmark selective PPARα agonist, enabling precise regulation of lipid metabolism and inflammation pathways. This article details advanced use-cases, workflow optimizations, and troubleshooting strategies that maximize the translational impact of WY-14643 in metabolic disorder and tumor microenvironment studies.

• Trelagliptin Promotes Osteoblast Differentiation via RUNX2 a

  2026-04-29

  This study reveals that trelagliptin, a DPP-4 inhibitor, significantly enhances osteoblastic differentiation in MC3T3-E1 cells by upregulating RUNX2 through an AMPK-dependent pathway. These findings suggest the therapeutic potential of trelagliptin for osteoporosis and illuminate mechanisms connecting metabolic and bone health.

• Temozolomide: Small-Molecule Alkylating Agent in Glioma Mode

  2026-04-29

  Temozolomide stands as the gold-standard small-molecule alkylating agent for modeling DNA damage and repair in cancer research, especially for dissecting glioma vulnerabilities and chemotherapy resistance. This article translates recent advances—including ATRX-deficient glioma insights—into actionable workflows, troubleshooting strategies, and precision assay design.

• Puromycin Aminonucleoside: Precision Tools for Podocyte Inju

  2026-04-28

  Puromycin aminonucleoside empowers researchers to induce and study podocyte injury and nephrotic syndrome with unmatched mechanistic precision. Leveraging advanced workflow enhancements and troubleshooting strategies, this gold-standard agent—available from APExBIO—drives reproducibility and depth in renal pathology investigation.

• Silybin A: Silymarin’s Precision in Liver Disease Research

  2026-04-28

  Silybin A, a principal component of Silymarin, offers targeted advantages for liver disease, fibrosis, and metabolic modulation studies. This article delivers executable protocols, troubleshooting insights, and evidence-driven comparisons that elevate experimental reproducibility and mechanistic clarity in hepatoprotective research.

15589 records 1/1040 page Next 12345 下5页 Last page